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Abstract
Mesenchymal stem cells (MSCs) have great potential as a source of cells for cell-based therapy because of their
ability for self-renewal and differentiation into functional cells. Moreover, matrix metalloproteinases (MMPs) have a
critical role in the differentiation of MSCs into different lineages. MSCs also interact with exogenous MMPs at their
surface, and regulate the pericellular localization of MMP activities. The fate of MSCs is regulated by specific MMPs
associated with a key cell lineage. Recent reports suggest the integration of MMPs in the differentiation,
angiogenesis, proliferation, and migration of MSCs. These interactions are not fully understood and warrant further
investigation, especially for their application as therapeutic tools to treat different diseases. Therefore,
overexpression of a single MMP or tissue-specific inhibitor of metalloproteinase in MSCs may promote
transdifferentiation into a specific cell lineage, which can be used for the treatment of some diseases. In this review,
we critically discuss the identification of various MMPs and the signaling pathways that affect the differentiation,
migration, angiogenesis, and proliferation of MSCs.
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Background
The extracellular matrix (ECM) plays many critical roles
including supplying information and signals to the sur-
rounding cells and providing structural support [1].
There are some molecules that are secreted by cells into
the ECM to control different biological activities at the
tissue or cellular level. Matrix metalloproteinases
(MMPs) are among the key molecules that regulate dif-
ferent molecular and biological events in the ECM.
MMPs are a family of zinc-dependent proteolytic en-
zymes involved in the degradation of ECM components.
MMPs were firstly named based on their substrates,
until it became clear that each MMP has multiple
substrates. Therefore, MMPs were classified into differ-
ent groups based on their domain structure, and the no-
menclature was changed to a numerical system [2].
MMPs are classified into several subgroups based on
their substrate preference or domain structure. Collage-
nases (MMP-1, MMP-8, MMP-13, and MMP-18) cleave
fibrillar collagen types I, II, and III, and they can cleave
other ECM proteins. Gelatinases (MMP-2 and MMP-9)
have high activity against gelatin, and degrade other
ECM molecules including collagens, laminin, and aggre-
can. Stromelysins (MMP-3, MMP-10, and MMP-11) di-
gest a number of noncollagen ECM molecules, and their
domain arrangement is similar to that of collagenases.
The membrane-type MMPs (MT-MMPs) (MMP-14,
MMP-15, MMP-16, MMP-17, MMP-24, and MMP-25)
are intracellularly activated transmembrane molecules,
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and their active forms are expressed on the cell surface.
There are other less characterized members including
MMP-7, MMP-12, MMP-19, MMP-20, MMP-22, and
MMP-23 [3]. Most of the MMPs contain the single pep-
tide, prodomain, catalytic domain, hinge domain, and
hemopexin domain. The MT-MMPs have an extra do-
main called the transmembrane domain or GPI-
anchored domain, which are integrated in the plasma
membrane [2].
MMPs are important in a wide variety of developmen-
tal processes including mediation of cell–cell adhesion,
tissue remodeling, cell migration, invasion, proliferation,
and apoptosis [3]. MMPs can cleave growth factor bind-
ing proteins or latent growth factors which may regulate
their synthesis and release from inside the cell [4, 5].
They are regulated by several MMP-specific inhibitors
called tissue-specific inhibitors of metalloproteinases
(TIMPs) [4, 5]. MMPs and TIMPs have a very critical
role in matrix remodeling that takes place during the re-
generation of any tissue [4, 5]. The activity and function
of MMPs suggest their involvement in different cellular
activities during cell development. This fact opens the
door to investigate the involvement of these enzymes in
the migration, proliferation, and differentiation of mes-
enchymal stem cells (MSCs).
Regenerative medicine is a promising approach that
involves stem cells and microenvironmental factors to
stimulate differentiation into different lineages. MSCs
have great potential as a source of cells for cell-based
therapy because of their ability for self-renewal and dif-
ferentiation into functional cells. MSCs are adult stem
cells of stromal origin that can be found in different bio-
logical sources not only in bone morrow, but also in
other various tissue sources [6]. They are multipotent
cells and are known to migrate from bone morrow to
different tissues with different compositions of ECM,
which justify the studies to examine their susceptibility
to matrix variation [7]. Moreover, it has been
demonstrated that MMPs have critical role in the differ-
entiation of MSCs to adipocytes, osteocytes, and chon-
drocytes [4]. MSCs also interact with exogenous MMPs
at their surface and activate proMMP-2 and proMMP-
13, regulating the pericellular localization of MMP activ-
ities [6]. They have the capability to regulate exogenous
MMP-2 and MMP-9 by the expression of TIMP-2 and
TIMP-1, protecting the perivascular niche from their
high levels [8].
There is increased interest in the use of MSCs as
therapeutic tools to treat different diseases because of
their ease of isolation, immune capability, expansion,
and proliferative and differentiation potency [9]. Re-
cently, the focus of many studies on MSCs is the con-
nection between cells and matrix signals. However, the
mechanisms that regulate the proliferation, migration,
self-renewal, and differentiation of MSCs are still not
fully understood [10]. Identifying the molecules that
regulate the fate of MSCs is an important approach to
understand how these cells can be controlled and thus
used as therapeutic tools. In this study, we critically
reviewed the findings on the effect of MMPs in angio-
genesis, migration, and proliferation of MSCs. We also
reviewed the role of MMPs on the multilineage property
of multisource-derived MSCs to differentiate into adipo-
cytes, chondrocytes, and osteocytes.
Role of MMPs in the differentiation of MSCs
Adipogenic differentiation
MMPs have been implicated in regulating adipogenic
differentiation of MSCs. MMPs and TIMPs have a cru-
cial role, either negative or positive, in the differentiation
of adipoblasts, which are derived from MSCs. Formation
of adipose tissue involves triggering of MSCs to differen-
tiate toward a preadipocyte lineage and finally to an adi-
pocyte lineage. This differentiation involves an increase
in the production and secretion of some MMPs [10]. It
was hypothesized that the formation of basement mem-
brane and remodeling of pericellular basement mem-
brane are required for the differentiation of MSCs to
adipocytes. Sillat and his group [11] studied the expres-
sion of basement membrane collagen type IV during the
adipogenic differentiation of MSCs. These investigators
found an increase in the expression of collagen type IV
by MSCs during adipogenesis, and the expression of
MMP-9 and TIMP-2 was significantly induced during
the differentiation. MMP-2 expression was localized in
the cytoplasm and close to the nucleus in the differenti-
ated and undifferentiated MSCs [11]. There was no sig-
nificant upregulation of MT1-MMP expression. These
data suggest that MSCs express collagen type IV, and se-
crete type IV collagenase (MMP-9) to remodel it during
adipogenic differentiation [11]. Although TIMPs have
been known to inhibit MMPs, the interaction of
proMMP-2 with TIMP-2 is required for the activation of
proMMP-2. TIMP-2 binds the catalytic domain of MT1-
MMP on the cell surface, and the C terminal of TIMP-2
recruits the endogenous proMMP-2 to the cell surface
and binds to it, forming the proMMP-2/TIMP-2/MT1-
MMP complex. Once this complex is formed, an active
MT1-MMP closely located to the complex cleaves the
prodomain and activates proMMP-2 [2]. However,
mouse embryonic cells overexpress MMP-2, and down-
regulate the expression of MMP-11 during adipogenic
differentiation in adipogenic differentiation medium.
Additionally, MMP-11-defecient mouse embryonic fi-
broblasts showed increased expression of adipocyte
markers compared with the wild type, indicating the
inhibitory effect of MMP-11 on the adipogenic differen-
tiation [12]. In a recent study, murine embryonic
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fibroblasts derived from MMP-2-deficient mice showed
impaired adipogenic differentiation as compared with
control murine embryonic fibroblasts derived from wild-
type mice. The MMP-2-deficient murine embryonic fi-
broblasts showed significant decreases in intracellular
lipid content and expression of adipogenic markers [13].
Moreover, the study also showed that selective knock-
down of MMP-2 in preadipocytes resulted in impaired
adipogenic differentiation, while the overexpression of
MMP-2 resulted in significantly enhanced adipogenic
differentiation [13]. A similar study investigated the role
of MMP-9 in adipogenic differentiation of preadipocytes.
The results showed that the silencing of MMP-9 did not
affect the intracellular lipid content or expression of adi-
pocyte specific markers, indicating that MMP-9 has no
effect on the differentiation of preadipocytes into adipo-
cytes [14]. However, several studies that examined the
role of MMP-9 in the adipogenic differentiation sug-
gested the positive regulatory role of MMP-9 in this
process. It is worth mentioning that studies with MMP
inhibitors lack specificity to a single MMP, and can in-
hibit MMP-2, MMP-9, and other proteases. In contrast,
this study was performed using MMP-9 shRNA silen-
cing, which did not show significant inhibitory effect on
the expression or activity level of MMP-2. Moreover,
broad-spectrum inhibitors can also inhibit a disintegrin
and metalloproteinases (ADAMs), affecting different
physiological processes. The expression of MMP-9 in
this study was upregulated in the first 2 days of stimula-
tion for adipogenic differentiation, followed by a rapid
decrease until the end of differentiation, suggesting that
the upregulation of MMP-9 does not necessarily have a
key role in this process [14]. In another study, treating
preadipocytes with a selective inhibitor for MMP-13 or
silencing MMP-13 by siRNA resulted in reduced adipo-
genic differentiation, suggesting the important role of
MMP-13 in adipogenesis [15].
Several MMPs and TIMPs have been shown to have a
positive or negative regulatory effect on the adipogenic
differentiation, indicating their distinct roles during the
commitment of differentiated cells. MMP-2 and MMP-9
were found to be upregulated during the differentiation
of preadipocytes to adipocytes, and the inhibition of
MMPs resulted in the suppression of adipogenic differ-
entiation [16]. Another study reported that MMP-13
was significantly upregulated during adipogenic differen-
tiation, while there was a significant downregulation in
the expression of TIMP-1, TIMP-2, and TIMP-3. The
findings from this study suggested an adjustment in the
expression of MMPs and TIMPs in the early stage of dif-
ferentiation to trigger the process toward a specific
lineage [17]. It has been also reported that MMP-9 regu-
lates the adipogenic differentiation by controlling the ex-
pression of adipogenic cytokines, including IL-1β, IL-8,
and IL-6 [18]. Furthermore, the expression of MMP-2
and MMP-9 was upregulated during the adipogenic dif-
ferentiation of preadipocytes with a decrease in the ex-
pression of TIMP-1 [19]. The effect of high-temperature
requirement proteases A1 (HTRA1) was found to have a
regulatory effect on MSCs undergoing adipogenic differ-
entiation through its impact on the expression of MMPs.
The treatment of MSCs with HTRA1 during adipogenic
differentiation showed a significant increase in mRNA
expression of MMP-1, MMP-2, MMP-3, MMP-9, and
MMP-13. At the protein level, the expression of MMP-3
and MMP-13 was significantly increased during adipo-
genic differentiation of MSCs with HTRA1. Moreover,
MMP inhibitors (NNGH and CL-82198) for MMP-3 and
MMP-13 during adipogenic differentiation increased the
level of collagen type IV in HTRA1-treated MSCs, sug-
gesting the important role of HTRA1 in inducing the ex-
pression of MMP-3 and MMP-13, and in adipogenic
differentiation of MSCs [20]. Fibronectin was found, in
vitro, to be produced first among all ECM components
during adipogenesis. Different types of collagen were se-
creted by differentiated cells and degraded during differ-
ent stages of the adipogenic differentiation. This
suggests that there are different MMPs and TIMPs
which are expressed during the adipogenic differenti-
ation to participate in the progress of this process by ei-
ther remodeling and/or degrading the ECM components
[21]. The involvement of MMPs and TIMPs, which have
so far been studied in the regulation of adipogenic differ-
entiation, reveals a crucial role of these enzymes in the
differentiation of MSCs to adipocytes.
Chondrogenic differentiation
ECM remodeling is a crucial process during skeletal for-
mation, which is required for chondrocyte progenitor
cells to undergo differentiation [10]. Although the role
of MMPs in vivo during chondrogenic differentiation is
still not clear, in-vitro studies have shown their crucial
role during this process. Chondrogenic differentiation of
human MSCs increases with the increase in collagen
concentration, yielding increased matrix production
[22]. This may indicate a direct or indirect role of MMPs
during the differentiation process, since they are import-
ant candidate molecules for communicating signals and
promoting the turnover of ECM molecules.
Jin and colleagues [23] investigated the role of MMP-2
in chondrogenic differentiation of MSCs. Their data
showed that the silencing of MMP-2 by siRNA impaired
chondrogenic differentiation, and increased the protein
level of fibronectin and β1 integrin. Treatment with a
MMP-2 activator resulted in the activation of chondro-
genesis. These results also indicated that the downregu-
lation of P38 mitogen-activated protein kinase (MAPK)
resulted in the inhibition of MMP-2 expression [23].
Almalki and Agrawal Stem Cell Research & Therapy  (2016) 7:129 Page 3 of 12
Moreover, MMP-2 is involved in the chondrogenic dif-
ferentiation of MSCs via downregulation of focal adhe-
sion kinase (FAK)–β1 integrin interaction, which leads
to phosphorylation of FAK (Fig. 1) [23]. In another
study, a group of scientists investigated the role of the
degradation of MMPs on the chondrogenesis of MSCs.
The study investigated the chondrogenic differentiation
in MMP-sensitive hydrolytically hydrogel scaffold in
comparison with MMP-insensitive hydrogels [24]. They
found that the MSCs in the MMP-sensitive hydrogels
had more morphological changes and chondrogenic
markers compared with MSCs in the MMP-insensitive
hydrogel group which remained round in shape [24]. A
similar study was carried out using degradable or nonde-
gradable polyethylene glycol gels. The human MSCs
were evaluated for their proliferation, morphology, and
chondrogenic differentiation in the two different gels.
MSCs in the degradable gel showed more morphological
changes and chondrogenic differentiation compared with
MSCs in nondegradable gel after 21 days [25]. These
studies revealed that the degradation of MMPs enhances
the chondrogenic differentiation of MSCs by allowing
the morphological changes and increasing the contents
of glycosaminoglycans (GAG) and expression of chon-
drogenic markers. A chondrogenic cell line (ATDC5)
was examined for chondrogenic differentiation, and the
expression of MMP-2, MMP-9, and MT1-MMP was up-
regulated during the early stages of chondrogenic differ-
entiation with a downregulation in the expression of
reversion-inducing cysteine-rich protein with Kazal mo-
tifs (RECK) [26]. However, RECK was shown to be up-
regulated in the later phase of differentiation. The
knockdown of RECK revealed a suppression in the later
ECM accumulation in the cartilaginous nodules. The
data suggested that RECK and MMPs have an important
effect in the chondrogenic differentiation through regu-
lating tissue morphogenesis (Fig. 1) [26]. Previous stud-
ies showed that the upregulation of MMP-13 occurs
during chondrogenic differentiation, and MMP-13 has
been found to be upregulated in patients with osteoarth-
ritis, suggesting a pathological role of MMP-13 in the
disease process. Salinas and her group monitored the ex-
pression of MMP-13 during chondrogenic differentiation
of MSCs, and they found an increased expression of
MMP-13 followed by an increase in GAG content by
day 9 until day 14 in vitro. The results indicate that the
increase in production of MMP-13 drives the MSC dif-
ferentiation to chondrocytes by degrading the cleavable
components of the ECM, and regulating integrin-
binding peptides [27].
Fig. 1 MMPs and chondrogenic differentiation of MSCs. The upregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK)
during the late stages of chondrogenic differentiation downregulates the expression of MT1-MMP (MMP-14), MMP-2, and MMP-9, and directly
inhibits them through its enzymatic activity. Expression of MMP-2 is upregulated by the increase in P38 activity resulting in stimulation of the
chondrogenic differentiation of MSCs. MMP-2 also regulates the association of FAK and β1 integrin through its degradation of fibronectin. This
degradation results in the inhibition of MAPK pathway through P38 to stop the production of more MMP-2 at late stages of the process. ECM
extracellular matrix, MMP matrix metalloproteinase, FAK focal adhesion kinase
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Although there is no direct connection between se-
creted proteins and MMP activity, it is clear that MMPs
play an important regulatory role during differentiation
of MSCs into chondrocytes. The role of MMP-13 during
skeletal repair and development is very crucial. The ab-
sence of MMP-13 affects the removal of hypertrophic
cartilage during nonstabilized fracture healing by MSCs.
MMP-13 produced by chondrocytes seems to be import-
ant in the initiation of cartilage degradation and recruit-
ment of blood vessels [28]. MSCs can also trigger
cartilage matrix remodeling by upregulating the expres-
sion of certain MMPs. MMP-13 was found to have an
important role in the later stages of chondrogenic differ-
entiation of MSCs by degrading the main components of
the cartilaginous matrix, aggrecan and type II collagen
[29]. Another study investigated the effect of ascorbic
acid 2 phosphate and type 1 atelocollagen on the in-
crease in collagen type II accumulation in scaffold-free
cartilage-like cell sheets prepared using human bone
marrow-derived MSCs. The study indicated that the syn-
thesis of collagen type II increased after ascorbic acid 2
phosphate and type 1 atelocollagen supplementation to
chondrogenic differentiation media [30]. Moreover, the
gene expression of MMP-13 was reduced compared with
control, suggesting a role for MMP-13 in the degrad-
ation of collagen type II during chondrogenic differenti-
ation [30]. Stimulation of MSCs in chondrogenic media
with IL-β1 resulted in increased expression of MMP-2,
MMP-3, and MMP-13 while IL-6 downregulated the ex-
pression of MMP-3 and MMP-13 compared with con-
trol without stimulation [31]. The knockdown of
discoidin domain receptor 1 in adipose-derived MSCs
(AMSCs) resulted in increased expression of chondro-
cyte specific markers, and impaired expression of runt-
related transcription factor 2 and MMP-13 during chon-
drogenic differentiation [32].
Osteogenic differentiation
Osteogenic differentiation and bone regeneration are
characterized by ECM remodeling and hormonal and
growth factor interactions. MSCs are very important
cells for bone regeneration because of their capability to
migrate into sites of injury and differentiate into osteo-
cytes. Bone undergoes different physiological processes,
including bone modeling and remodeling. Bone model-
ing leads to a change in bone shape in response to bio-
mechanical forces. However, bone remodeling maintains
bone strength through the resorption of old bones and
the formation of new bones by dependent actions of os-
teoclasts and osteoblasts [33]. The differentiation of os-
teoblasts and bone formation are controlled by bone
morphogenetic protein (BMP) and wingless (Wnt) sig-
naling pathways, leading to the synthesis of collagen type
I, whereas osteoclast differentiation is controlled by the
receptor activator of nuclear factor kB (RANK) signaling
pathway through macrophage colony-stimulating factor
(MCSF) [34]. The role of MMPs on osteogenic differen-
tiation has been studied, and their effect in osteoclastic
resorption has been supported by studies indicating that
MMP inhibition may block the osteoclastogenesis. Spe-
cific inhibition of several MMPs showed an important
role for MMP-13 in MSC differentiation to osteocytes.
The inhibition of MMPs by a broad-spectrum inhibitor
revealed a huge alteration in osteogenic differentiation
of MSCs [35]. These findings suggest that MSC differen-
tiation is correlated with MMP and TIMP activity and
the balance between the two molecules [35]. In another
study, a broad-spectrum inhibitor for MMPs was used
to determine the need for ECM remodeling during
osteogenic differentiation of preosteoblasts, and the data
revealed that MMP activity is necessary for the transi-
tion to osteoblasts [36]. The absence of MMP-13 affects
the remodeling process during osteogenesis and after
bone marrow transplantation, suggesting its key role in
the osteogenic differentiation. This indicates that MMP-
13 is involved in skeletal repair, and acts in the early
stages of ECM degradation prior to invasion of osteo-
clasts and blood vessels [28]. Manduca and colleagues
[37] have investigated the role of MMPs in osteogenic
differentiation. In this study, the plating of preosteo-
blasts on MMP-inducing substrata resulted in the for-
mation of β1 integrin complexed with MT1-MMP. The
MT1-MMP senses the surrounding microenvironment
through the binding of β1 integrin and the ECM. More-
over, overexpressing MT1-MMP during osteogenic
differentiation was found to upregulate alkaline phos-
phatase (ALP) which is involved in crystal deposition on
the scaffold of collagen type I fibers in the ECM of oste-
oblasts. The data suggest that MT1-MMP expression is
crucial in the formation of nodules and mineral depos-
ition during osteogenic differentiation. The expression of
MT1-MMP during osteogenesis allows ECM remodel-
ing, and initiates the expression of ALP and proMMP-2
(Fig. 2) [37].
MSCs have the ability to adjust the expression pheno-
type of MMPs and TIMPs to modify and maintain the
ECM in a structural state optimal for differentiation into
a specific lineage. When human MSCs were stimulated
for osteogenic differentiation, the expression of MMPs
and TIMPs was adjusted to promote the structural con-
formation and ECM remodeling optimal to osteogenic
differentiation. There was a decrease in the expression
of MMP-1 and MMP-8 with an increase in the expres-
sion of TIMP-2 and TIMP-4. The results indicate that
TIMPs and MMPs are upregulated or downregulated in
differentiation-specific manners [38]. MSCs, in culture,
express some MMPs including MMP-1, MMP-2, MMP-
13, MT1-MMP, and MT3-MMP. However, MMP
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expression can be modulated by the composition of cul-
ture. During stimulation of MSCs for osteogenic differ-
entiation, silencing each of the MMPs mentioned earlier
showed that MT1-MMP is the only MMP that is re-
sponsible for MSC-mediated type I collagenolysis. In 3D
culture, MSCs express ALP activity with inhibition of
TIMP-2 activity. Silencing MT1-MMP resulted in im-
paired morphological change of MSCs and ALP expres-
sion, and the cells failed to undergo osteogenic
differentiation. The inability of MSCs to undergo osteo-
genic differentiation was rescued by adding mouse
MT1-MMP [39]. In 2D culture, MT1-MMP silencing
did not affect the osteogenic differentiation of MSCs
[39]. To study the role of extracellular signal-related kin-
ase (ERK) in collagen-induced osteogenic differentiation
of MSCs, a mitogen-activated protein kinase (MEK) in-
hibitor was used in 2D and 3D cultures. The data indi-
cated that osteogenic differentiation is ERK-mediated
differentiation [40]. Moreover, the osteoblastic differenti-
ation of MSCs was increased after X-ray irradiation with
a decrease in the expression of collagen I and II, which
was due to significant increase in the expression of
MMP-3 and MMP-13 [41]. However, another study
examining the expression profile of mice bone marrow-
derived MSCs showed that the expression of MMP-13,
MMP-3, and MMP-2 was downregulated during
osteogenic differentiation [42]. To study the role of sox9
on the osteogenic differentiation of AMSCs, sox9 was
knocked down by shRNA, which resulted in increased
expression of osteocalcin, vascular endothelial growth
factor alpha (VEGF-α), and MMP-13 in the early stages
of differentiation [43].
Endothelial differentiation
MSC therapy can be used for regeneration of the injured
endothelial layer. The endothelial differentiation of
MSCs derived from different sources has been reported
[44–50]. Even though MMPs were initially reported to
have an ability to degrade the ECM, MMPs are now
known to regulate many biological processes, being in-
volved not only in physiological events but also in patho-
logical processes [51]. MMPs and their inhibitors have
important roles in mediating cell–cell adhesion, cell mi-
gration and invasion, cell proliferation, apoptosis, and
tissue remodeling [1]. MMPs promote the release of
ECM-bound or cell surface-bound cytokines, which then
regulate the differentiation of stem cells [52, 53]. It has
been suggested that ECM signaling regulates endothelial
cell (EC) morphogenesis and induction of angiogenesis.
ECM signaling can therefore be coincident with degrad-
ation of the ECM and exposure of ECs to collagen type I
[1]. The ECM remodeling by MMPs has a key role in
Fig. 2 MMPs and osteogenic differentiation of MSCs. β1 integrins engage with fibronectin and collagen type I in the ECM, resulting in the
formation of MT1-MMP and β1 integrin complex. This complex initiates the expression of proMMP-2 and ALP, which is required for the formation
of nodules and their mineralization, and allows the activation of proMMP-2 through MT1-MMP during the osteogenic differentiation. ECM
extracellular matrix, MMP matrix metalloproteinase, MT-MMP membrane type-matrix metalloproteinase
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angiogenesis, migration, and morphogenic differentiation
of ECs [54]. Moreover, it was demonstrated that the re-
cruitment of stem and endothelial progenitor cells from
the quiescent niche in bone marrow is dependent on
MMP-9, which enhances cell mobility and rapid differ-
entiation [55]. Therefore, MMP expression could be
transiently manipulated to induce differentiation of
MSCs into ECs. The role of MMPs in the differentiation
of MSCs to different lineages has been reported previ-
ously. To date, there are no published data that show
the relationship between MMPs and endothelial differ-
entiation of MSCs. In our laboratory, we studied the
expression of a group of MMPs and TIMPs to evaluate
their role on the differentiation of AMSCs to ECs. The
study is still under investigation and is designed to evalu-
ate the expression and effect of MMPs and TIMPs at three
time points during EC differentiation of AMSCs.
MSCs express MMPs and TIMPs to regulate
different processes
Angiogenesis
The role of MMPs in angiogenesis is important for
therapeutic angiogenesis and tissue engineering to en-
hance blood vessel growth and nutrient delivery after
myocardial infarction. TIMP-3, for instance, was found
to block VEGF receptors and inhibit VEGF-mediated
angiogenesis [56]. Further, the downregulation of MMP-
2 and MT1-MMP expression by UVA irradiation was
found to inhibit angiogenesis [57].
MSCs transfected with VEGF/HGF delivered through
the coronary vein into infarcted pig heart were shown to
increase cardiac function by improving the angiogenesis
process in the injured tissue [58]. At present, MSCs are
known for their ability to influence the behavior of ECs,
and promote their formation of capillary-like structures.
MMPs that are expressed by MSCs can contribute to
that role during the interaction of MSCs and ECs [4].
Glaeser and colleagues [59] demonstrated that the inhib-
ition of MMP-2 attenuated the tube-like formation.
Under mechanical stimulation by MSCs, the secretion of
proMMP-2 and the activity of MMP-2 were induced
and, as a result, this induction contributes to angiogen-
esis stimulation. It was also demonstrated in another
study that mechanically stimulated MSCs have higher
angiogenic properties with an observed enhancement in
the activity of MMP-2 compared with unstimulated
MSCs [4, 33].
MSCs have angiogenic properties that involve degrad-
ation of ECM. This was supported by an in-vitro study
that showed an induction of MSC capillary-like structure
formation in hypoxic culture condition. Further, it was
noticed that MT1-MMP expression was significantly up-
regulated, and the inhibition of MT1-MMP reduced the
capability of MSCs to form capillary-like structures.
These data suggest that MT1-MMP has an important
regulatory role in ECM remodeling and MSC capillary-
like structure formation [60]. The addition of MSCs to
ECs in 3D fibrin matrices resulted in an increased matrix
density and network formation. It was also predicted
that MMP-2, MMP-9, and MT1-MMP expressions were
upregulated after the addition of MSCs. However, the
data revealed that only MT1-MMP among these prote-
ases has a crucial role in facilitating the angiogenesis
process. These results suggest that MT1-MMP can act
locally to mediate ECM degradation and allow the re-
lease of matrix-bound growth factors that are important
for angiogenesis [61]. Intravenous administration of
bone marrow-derived MSCs after middle cerebral artery
occlusion in a rat model resulted in increased activity of
MMP-2 and vascular density, and in reduced infarction
volume suggesting the important role of MMP-2 activity
and MSCs in promoting angiogenesis [62]. Moreover,
coculturing of human amniotic MSCs or bone marrow-
derived MSCs with human umbilical vein ECs, seeded in
fibrin gels and injected subcutaneously into mice, was
done to evaluate their angiogenic capacity. The results
showed increased expression of platelet endothelial cell
adhesion molecule (PECAM) and vessel-like structure
density compared with human umbilical vein EC mono-
culture [56]. The in-vitro experiment showed signifi-
cantly increased formation of capillary-like structures in
coculture with a significant increase in the activity of
MMP-2 and MMP-9 compared with human umbilical
vein EC monoculture [63]. Inhibition of MMPs by
broad-spectrum inhibitor in platelet fibrin gel and car-
diac stem cells, when cotransplanted into rat hearts with
myocardial infarction, resulted in impaired functional
and structural benefits of cell gel in treating myocardial
infarction, and reduced host angiogenesis [64]. Overex-
pression of miR-195a-3p, which is highly expressed in
MSCs, was found to decrease angiogenesis through the
inhibition of MMP-2 and activation of anti-angiogenic
factor pigment epithelium-derived factor, suggesting a
therapeutic potential of miR-195a-3p as an inhibitor for
angiogenesis [65].
Proliferation
In order to use MSC transplantation in tissue regener-
ation as a therapeutic tool, we need to know the mole-
cules and signaling pathways that participate and control
MSC expansion. The remodeling of the pericellular
matrix of MSCs is a prerequisite for these cells to prolif-
erate [66]. The role of a histone deacetylase inhibitor
(valproic acid) in regulating MSC proliferation was ex-
amined. The data revealed an increase in the expression
level of proliferation markers associated with an in-
creased expression of proMMP-2 and MMP-2, suggest-
ing an important role for MMP-2 during this process
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[67]. Shi and his group [66] studied the role of MMPs in
the proliferation of MSCs using MT3-MMP-deficient
mice and found growth inhibition as a result of a de-
crease in MSC viability. This finding suggested that
MT3-MMP has a key role in collagenolysis by allowing
other surrounding cells to degrade high-density fibrillar
collagen and make the ECM permissive for proliferation.
In MT1-MMP and MT3-MMP double-deficient mice,
the results indicated a severe effect of MT1-MMP defi-
ciency in bone formation. Altogether, the results re-
vealed that the deficiency of both MT1-MMP and MT3-
MMP leads to severe defects as a result of lack in col-
lagenolytic activity that is required for ECM remodeling
and cell proliferation [66].
MMPs and TIMPs are important for ECM remodeling,
affecting MSC behavior during their proliferation.
Broad-spectrum inhibition of MMPs affects the prolifer-
ative capacity of MSCs. Protein and mRNA analysis de-
tected the expression of MMP-2, MMP-3, MMP-10,
MMP-11, MMP-13, MT1-MMP, and TIMP-2 in MSCs.
Mechanical stimulation of MSCs resulted in increased
protein expression, but not mRNA expression, of MMP-
2, MMP-3, MMP-13, and TIMP-2. These findings sug-
gest that secretion or activation of these MMPs is af-
fected by posttranscriptional regulation in response to
mechanical stimuli, and MMP/TIMP balance is import-
ant in the regulation of this process [33]. Broad-
spectrum inhibitors for MMPs resulted in a significant
decrease in the proliferative activity of MSCs [33]. More-
over, it was found that MT1-MMP expression is upregu-
lated by PDGF-BB, which resulted in an increase in the
proliferative activity of MSCs. However, the inhibition of
ERK1/2 and PI3K/AKT leads to the inhibition of MT1-
MMP and proliferative activity of MSCs. These data re-
vealed an important role for MT1-MMP in the invasive
and proliferative activity of MSCs which are regulated by
the ERK1/2 and PI3K/AKT signaling pathways [68].
Overexpression of miR-195a-3p was also found to de-
crease MSC proliferation through the inhibition of
MMP-2 [65]. The incubation of dermal fibroblasts
with conditioned medium of umbilical cord blood-
derived MSCs increased the proliferation of dermal fi-
broblasts with an increased ratio of MMP/TIMP [69].
Microvesicles are cell-derived vesicles released by dif-
ferent type of cells into the ECM and fuse with
neighboring cells to transfer protein and RNA. They
are classified into exosomes and ectosomes [70–72].
The interactions between cancer cells, ECs, and MSCs
via microvesicles were examined. MSCs were treated
with microvesicles isolated from conditioned medium
of ECs or cancer cells, and such treatment of micro-
vesicles increased the proliferation and migration of
MSCs together with an increase in MMP-1 and
MMP-3 [73].
Migration
In order for cells to migrate, they undergo molecular
and structural changes to move from an adhesive pheno-
type to a migratory phenotype [3]. MMPs have an
essential role in regulating the migratory activity of
transformed cells. The degradation products that result
from MMP proteolysis of ECM also have a mediatory ef-
fect on cell migration [2]. Migratory behavior of MSCs
involves MMP activity. MSC migration was found to be
impaired by a broad-spectrum MMP inhibitor [4].
MMP-2 inhibition in tumor cells was also found to de-
crease MSC migration through the inhibition of SDF1/
CXCR4 signaling, which indicates a mediatory effect for
MMP-2 in the migration of MSCs [74]. MSCs express
CXCR4, MMP-2, and MT1-MMP to increase mobility
and promote migration and recruitment of expanded
MSCs to injured tissues [75]. Valproic acid, a histone
deacetylase inhibitor, enhances MSC migration through
the upregulation of both CXCR4 and MMP-2 expression
[67]. Further, enhanced gene expression of CXCR4,
MMP-2, and MMP-9 by heat shock protein 90 (Hsp90)
leads to an increase in the migratory behavior of MSCs
[76]. MMP-2 was also found to have a positive role in
the transendothelial migration of MSCs, while the in-
crease in culture confluency of MSCs along with MMP-
2 siRNA inhibition decreased the transendothelial mi-
gration of MSCs and increased the expression of TIMP-
3 [77]. The expression of MMP-2 can be downregulated
by norepinephrine via β3-adrenergic receptor (adrb3) in
MSCs and inhibits the migratory behavior of MSCs from
perivascular regions to bone-forming units. Silencing
adrb3 decreases the inhibition of MSC migration by up-
regulating MMP-2 expression and downregulating
TIMP-3 expression [78]. The overexpression of miR-
195a-3p was also found to impair MSC migration via
the inhibition of MMP-2 [65].
Ries et al. [51] analyzed the expression of MMPs and
TIMPs in bone marrow-derived MSCs. The results
showed that bone marrow-derived MSCs highly express
MMP-2, MT1-MMP, TIMP-1, and TIMP-2. However, si-
lencing MMP-2, MT1-MMP, or TIMP-2 decreased MSC
migration, whereas TIMP-1 knockdown promoted the
process. It was also indicated that TGF-β1, TNF-α, and
IL-1β upregulate the expression of MMP-2, MT1-MMP,
and TIMP-2, which also lead to the activation of MSC
migration. These findings revealed that MMP-2 and
MT1-MMP have an essential role in MSC migration,
and they can be induced by some cytokines in vivo to in-
crease the recruitment and migration of MSCs to the in-
jured tissue [51]. The findings of this study support the
role of MMP-2 in MSC migration. In another study, a
group of scientists demonstrated the effect of hypoxic
culture in stimulating the migration of MSCs in vitro.
They found that treating the cells with cytokine-enriched
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medium and hypoxic conditions induce the migratory be-
havior of MSCs with a downregulation in MMP-2 and up-
regulation in MT1-MMP expressions. The inhibition of
MT1-MMP also revealed its important role in stimulating
the migration of MSCs [60, 79]. Lu et al. [39] also indi-
cated that MT1-MMP has a critical role in MSC migra-
tion by degrading and penetrating collagen type I
networks. Specific inhibition of MT1-MMP impaired the
migration of MSCs, and this was reversed after transfect-
ing the cells with MT1-MMP expression vector [39].
Treatment of human umbilical cord blood-derived MSCs
with arachidonic acid, which is released during injuries,
was reported to induce fibronectin degradation by MT3-
MMP through the phosphorylation of p38 MAPK and
transcription factor Sp1, and stimulated the MSC motility.
The arachidonic acid treatment also enhanced skin wound
healing in vivo through induction of MSC motility by
MT3-MMP degradation activity [80]. Furthermore, the in-
cubation of dermal fibroblasts with a condition medium
from umbilical cord-derived MSCs was found to enhance
the migration of dermal fibroblasts with increased ratio of
MMP/TIMP [69]. Several studies have reported the MSC
migration to the sites of tumor, suggesting the role of spe-
cific signals in activating MSC migration. The incubation
of MSCs with conditioned medium of hepatoma cell cul-
ture was found to increase MSC migration by significantly
increased levels of MIP-1δ, MIP-3α, and MMP-1, suggest-
ing the dependency of MSC migration on MMP-1 [81]. In
a recent study, the effect of a conditioned medium of bone
marrow-derived MSCs on the proliferation and photo-
aging of dermal fibroblasts after UV exposure was in-
vestigated. The results showed that MSC conditioned
medium significantly reduced the UV-induced expres-
sion of MMP-1 and increased procollagen synthesis,
suggesting a therapeutic potential of MSC-conditioned
medium in preventing dermal damage through MMP-
1 downregulation [82].
A comparison between the expressions of some genes in
the MSC isolates showed that the increase in MMP-1 ex-
pression was associated with highly migrating MSCs com-
pared with those with poor migration [83]. The inhibition
of MMP-1 revealed a significant decrease in MSC migra-
tion. Similarly, blocking the interaction of MMP-1 and
protease-activated receptors (PAR1) resulted in the inhib-
ition of MSC migration [83]. Inhibition of hypoxia-
inducible factor 1 alpha (HIF-α) in MSCs was shown to
decrease the expression of MMP-1 and MMP-3, resulting
in poor migration. These findings suggest the important
role of MMP-1 in addition to MMP-3 in MSC migration
via HIF-α [84].
Conclusion
MSCs are potent cells for normal regenerative processes
because of their ability for self-renewal and differentiation
into different lineages [79, 80]. Commitment of MSCs to
differentiate into a specific lineage, proliferate, or migrate
is regulated by many factors in the local tissue microenvir-
onment. Each of these types of cells is associated with ex-
pression of a distinct set of proteins. However, there are
many challenges to dissect the underlying regulatory
mechanisms in the differentiation and function of MSCs.
These challenges include the identification of MMPs and
TIMPs as well as the crosstalk between signaling pathways
that promote self-renewal, migration, proliferation, and
lineage differentiation in MSCs. The ability of MMPs to
regulate and/or change the function and activity of differ-
ent proteins and receptors suggest that they may also be
involved in controlling the commitment of MSCs. Since
MMPs degrade all of the components of ECM, their role
in controlling and regulating matrix functions has been
studied extensively. The potential of MSCs to differentiate
into a particular mesenchymal lineage relies upon upregu-
lation or suppression of genes specific to this lineage.
In summary, the differentiation of MSCs into each of
these cell lineages is promoted by specific MMPs and/or
TIMPs associated with a specific cell lineage. MMP-9,
MMP-2, MMP-11, MMP-13, and TIMP-1 are key regu-
lators that have a crucial role in the differentiation of
MSCs toward adipocytes. MMP-13 and MT-1MMP, in
addition to MMP-2 and MMP-9, play a key role in the
differentiation of MSCs to chondrocytes. MMP-1,
MMP-3, MMP-13, and MT1-MMP are the MMP regu-
lators for osteogenic differentiation of MSCs (Fig. 3).
Moreover, TIMP-2 was also found to have a role in this
differentiation. Both MMP-2 and MT1-MMP have a key
role in the angiogenesis, proliferation, and migration of
MSCs. In addition, MMP-1, MMP-3, and MT3-MMP
have a regulatory effect in MSC proliferation, while
MMP-9 was found to have an effect on the angiogenic
activity of MSCs. MMP-1, MMP-3, TIMP-1, and TIMP-
2 also play an important role in MSC migration (Fig. 3).
There are only a few studies addressing the mecha-
nisms behind the effect of MMPs on MSC differenti-
ation. The binding associations between MMPs and cell
surface receptors suggest a direct effect of MMPs to trig-
ger the signaling pathways involved in MSC migration,
proliferation, growth, and differentiation. MMP-2 can
bind to αVβ3 on the cell surface of MSCs, and the mes-
enchymal invasive behavior may depend on this binding.
In epithelial cells, the binding of proMMP-2 to αVβ3 re-
sulted in increased expression of VEGF and angiogenesis
through the PI3K/AKT pathway [85], suggesting a po-
tential mechanism for the effect of MMPs on the angio-
genic activity of MSCs. Moreover, the binding of
proMMP-9 to α4β1 integrin and CD44 was found to in-
duce chronic B-lymphocytic leukemia survival through
the activation of an intracellular signaling pathway,
which results in STAT3 phosphorylation and induced
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myeloid leukemia cell differentiation protein (Mcl-1) up-
regulation [85]. It has also been reported that angioten-
sin II (Ang II) induces the expression of MMP-2 and
MMP-14 through the activation of the MAPK signaling
pathway [86], indicating a critical role of Ang II in the
expression of MMP-2 and MMP-14. The binding of
TIMP-1 to CD63 on the plasma membrane of MSCs
promotes the degradation of β-catenin, and knockdown
of TIMP-1 stimulates the activity of β-catenin and pro-
motes osteogenic differentiation through the Wnt/β-ca-
tenin signaling pathway [87]. In sum, this represents
possible interactions between MMPs and MSC surface
molecules or/and intracellular signaling pathways in-
volved in a major biological events in MSCs. However,
there is still a lack of information about the mechanisms
that regulate the expression and effective roles of MMPs
in the differentiation of MSCs into different mesenchy-
mal lineages. MMPs are critical molecules in a wide var-
iety of developmental processes including mediating
cell–cell adhesion, tissue remodeling, cell migration, in-
vasion, proliferation, and apoptosis [3]. The activity and
function of MMPs suggest their involvement in different
cellular activities during cell development. They have a
critical role in matrix remodeling that takes place during
the regeneration of any tissue [4]. Further research is
warranted in the field of MMPs and their regulatory ef-
fects on the fate of MSCs. However, the complex nature
of the proteolytic environment makes it difficult to study
the MSC-MMP and MSC–matrix interactions. These in-
teractions need further examination to control the fate
of MSCs and utilization of such knowledge for transla-
tional purposes. Overall, the findings support the crucial
role of MMPs in promoting the differentiation,
angiogenesis, proliferation, and migration of MSCs. How-
ever, the conflicting data warrant more careful and con-
trolled studies for better understanding of the process.
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